A study to evaluate the safety, tolerability, PK, and PD effects of AZD2389 in participants with liver fibrosis and compensated cirrhosis.

Trial Identifier: D7930C00002
Sponsor: AstraZeneca
Start Date: December 2024
Primary Completion Date: July 2025
Study Completion Date: July 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
GB Cambridge, GB, CB2 0QQ
US, AZ Chandler, AZ, US, 85224
US, CA Rialto, CA, US, 92377
US, GA Atlanta, GA, US, 30349
US, NC Morehead City, NC, US, 28557
US, PR San Juan, PR, US, 00927
US, TX Houston, TX, US, 77079
US, TX San Antonio, TX, US, 78215
US, TX San Antonio, TX, US, 78229